Titan Biotech Ltd Management Discussions.

Industry Structure & Development

The global biotechnology market is expected to reach USD 727.10 according to a new report by Grand View Research Inc. The emergence of certain key themes in the biotechnology market is expected to drive growth in this industry to a lucrative extent.

These key themes include regenerative medicine and genetics in diagnostics. Presence of a plethora of companies focusing on the development of regenerative therapies is anticipated to drive sector growth through to 2025. Technological advancements pertaining to the penetration of artificial intelligence in this industry is expected to fuel progress with potential avenues. The companies are engaged in unleashing machine learning in order to understand individual cancer cases, while recommending clinical trials.

Opportunity and Threats

Stiff Competition both on domestic and International level poses some threat to the market share of company but since the market is quite large, the same is easily absorbed. The Global Biotech Market is open and the opportunity to tap the global market is immense. The Company has maintained its market share during 2018-2019 and is regularly encashing on all opportunities. Your Company has maintained its quality standards and always working towards improvements. New Technology Developments and New Product Developments do take place and updating in terms of technology and quality is the need of the hour. Though Company does not expect any major threats yet it is cautious in all its endeavours.

Segment wise or product wise performance

The Company has only one segment i.e. biological goods.


The outlook of the Biotechnology sector is quite good in the last year and continue to be good presently also. Biotech is among one of the sectors which have highlighted the profile of the country in the last decade. At the beginning of the decade itself, this industry began to take shape with the sprouting of dozens of start up companies as well as diversification of major pharma players by setting up biotech divisions to focus on this segment. With the country offering great comparative advantages in terms of skills, knowledge, expertise, cost effectiveness, the Outlook of the Industry looks very positive.

Risk and Concern

The major risk is frequent increase in price of few raw materials which can increase cost of product and can make few products unprofitable unless the increase is passed on to the user which may at times be difficult due to stiff competition. Further, delay in grant of approvals can result in delay in launching of key products in the market. In addition significant competition in key products could also affect market share and profitability of the Company.

Internal Control System and their Adequacy

Titan Biotech Limited has well established internal control systems for operations of the Company. All the departments of the company including the accounts & finance department has experienced and trained staff capable of implementing and monitoring internal control systems. The internal control system of the Company is adequate to safeguard the Companys assets and to ensure that the transactions are properly recorded. Further, the internal control system ensures that proper record are being kept and all statutory and other laws, rules and regulations are being complied with.

Financial performance vis-a-vis operational performance

The performance of the Company from operation was better as compared to previous year turnover increasing from Rs. 5782.04 lakhs to Rs. 6559.45 Lakhs in consolidated figures whereas in standalone the turnover is 5597.56 lakhs to 5889.17 lakhs. The profitability of the Company also improves with net profit increasing in consolidated figures from Rs. 266.79 Lakhs to Rs. 391.22 lakhs whereas in standalone figures the 240.13 lakhs to 308.03 lakhs.

Material Development in Human Resources

There has not been any major development on the human resources front. The industrial relation continues to be cordial during the year 2018-19. The no. of permanent employees on the rolls of Company as on 31st March, 2019 was 226.


Your Directors would like to express their grateful appreciation for the assistance and continued cooperation extended by the Bankers, Government Agencies, Shareholders, customers, and wish to place on record their deep sense of commitment shown by the employees at all levels and acknowledge their contribution for the smooth operation of the Company during the year under report.

For Titan Biotech Limited For Titan Biotech Limited
Suresh Chand Singla Naresh Kumar Singla
Date: 02.09.2019 Managing Director Managing Director
Place: Delhi DIN 00027706 DIN 00027448